InterventionsHumans5,608 participantsCohort studyDeclared ties to: Mayo Clinic, Elsevier, AstraZeneca and 9 more

SGLT2 inhibitors versus GLP-1 receptor agonists and risk of kidney replacement therapy and healthcare utilization in bipolar disorder with chronic kidney disease: An active-comparator, new-user cohort study

Journal of Affective Disorders

The paper

Balwinder Singh, Feyza Yaylaci, Hossam M. Ali,

Ritika Baweja, Maria L. Gonzalez Suarez,

Raman K. Baweja

Mayo Clinic · Pennsylvania State University

Journal of Affective Disorders · 22 Aug 2026

doi.org/10.1016/j.jad.2026.122407 PubMed 42632571

SGLT2 inhibitors raise genital but not urinary infection risk
Clinical Pharmacology and Therapeutics · 4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease
The American Journal of Cardiology · 8 Oct 2026